Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.41
+3.1%
$0.75
$0.36
▼
$1.73
$114.67M0.245.22 million shs3.63 million shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$32.80
-2.0%
$32.85
$16.01
▼
$36.88
$62.96B0.54316,493 shs666,955 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$48.84
-0.8%
$49.32
$45.81
▼
$61.69
$98.76B0.294.43 million shs1.01 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$48.84
-0.8%
$49.32
$45.81
▼
$61.69
$98.76B0.294.43 million shs1.01 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-10.74%-26.10%-40.24%-54.78%-77.25%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-1.56%-2.84%+0.45%+12.35%-42.26%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-2.29%-3.93%-0.58%-6.92%+3.80%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-2.29%-3.93%-0.58%-6.92%+3.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.41
+3.1%
$0.75
$0.36
▼
$1.73
$114.67M0.245.22 million shs3.63 million shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$32.80
-2.0%
$32.85
$16.01
▼
$36.88
$62.96B0.54316,493 shs666,955 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$48.84
-0.8%
$49.32
$45.81
▼
$61.69
$98.76B0.294.43 million shs1.01 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$48.84
-0.8%
$49.32
$45.81
▼
$61.69
$98.76B0.294.43 million shs1.01 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-10.74%-26.10%-40.24%-54.78%-77.25%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-1.56%-2.84%+0.45%+12.35%-42.26%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-2.29%-3.93%-0.58%-6.92%+3.80%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-2.29%-3.93%-0.58%-6.92%+3.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.43
Hold$3.50747.46% Upside
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
2.20
HoldN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.00
Hold$56.3015.27% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.00
Hold$56.3015.27% Upside

Current Analyst Ratings Breakdown

Latest AKBA, CSLLY, GSK, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Lower Price TargetOverweight$2.00
10/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
DowngradeBuy ➝ Hold$67.40 ➝ $55.90
10/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
DowngradeBuy ➝ Hold$67.40 ➝ $55.90
10/27/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingHold (C+)
10/27/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingHold (C+)
10/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Initiated CoverageOutperform$70.00
10/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Initiated CoverageOutperform$70.00
10/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingBuy
10/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingBuy
10/2/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
10/1/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingSell
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M0.49N/AN/A$0.07 per share5.90
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$15.80B3.99$2.08 per share15.74$8.51 per share3.85
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.29$5.81 per share8.40$12.21 per share4.00
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.29$5.81 per share8.40$12.21 per share4.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.16N/AN/AN/A-22.60%-156.59%-11.53%N/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-$2.58BN/AN/A19.412.86N/AN/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$2.8816.969.792.2713.00%41.41%11.09%2/3/2027 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$2.8816.969.792.2713.00%41.41%11.09%2/3/2027 (Estimated)

Latest AKBA, CSLLY, GSK, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0360-$0.04-$0.0040-$0.05$46.94 million$36.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$0.722.20%N/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.783.64%-7.86%61.81%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.783.64%-7.86%61.81%N/A

Latest AKBA, CSLLY, GSK, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45183.58%11/13/202611/13/20261/7/2027
10/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45183.58%11/13/202611/13/20261/7/2027
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.63
1.36
1.24
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.60
2.21
0.97
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.18
0.86
0.56
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.18
0.86
0.56

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.03%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
194277.66 million265.72 millionOptionable
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
29,0001.92 billionN/ANot Optionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable

Recent News About These Companies

GSK Gets FDA Approval for New Lung-Cancer Drug
FDA grants accelerated approval to GSK's lung cancer drug
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
GSK: 3 Key Takeaways for Long-Term Investors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$0.41 +0.01 (+3.15%)
As of 12:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CSL stock logo

CSL OTCMKTS:CSLLY

$32.80 -0.67 (-2.00%)
As of 12:17 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK stock logo

GSK NYSE:GSK

$48.84 -0.40 (-0.81%)
As of 12:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$48.84 -0.40 (-0.81%)
As of 12:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.